NantHealth’s Eviti Connect Data Shows Recycling of Chemotherapy and Biologics for Advanced CRC Patients More Common Than Switching to Drug Regimens with Alternative Mechanism of Action
NantHealth Presented These Findings at the
The Symposium, held at the
NantHealth’s presentation examined therapeutic preferences and treatment patterns among advanced CRC patients using data from NantHealth’s Eviti Connect, an evidence-based treatment intelligence and web-based oncology decision support platform. Detailed information from 6,325 treatment plans was analyzed to identify treatment patterns using regorafenib and trifluridine + tipiracil for advanced CRC patients as third-line of therapy. National Comprehensive Cancer Network (NCCN) guidelines state that regorafenib and trifluridine+tipiracil are both treatment options for patients who have progressed through all available regimens.
Across all 6,325 treatment plans submitted for this patient population, regorafenib (n=217) or trifluridine+tipiracil (n=144) was the submitted treatment in 361 (5.5%) of the treatment plans, making them the 9th and 13th most frequently requested drugs (excluding growth factors, anti-emetics, and leucovorin) in this setting. While the total number of treatment plans for regorafenib was higher than that for trifluridine+tipiracil, the submission of trifluridine+tipiracil has increased over time, consistent with the latter drug’s more recent introduction into the market.
“Our analysis shows that recycling of chemotherapy and biologics in the late line setting is common and occurs more frequently than switching to a drug regimen with an alternative mechanism of action,” said
Title: “Real world data on treatment patterns of advanced CRC in 3rd line and beyond”
Abstract #56, Poster Session and Number: C – Anal and Colorectal Cancer
Date and Time:
“Our Eviti platform enables access to near-real time data on physician behavior which can provide unique and critical information to pharma, payers, and provider networks to optimize treatment strategies,” said Sandeep “Bobby” Reddy, MD, Chief Medical Officer,
This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. Risks and uncertainties include, but are not limited to: our ability to successfully integrate a complex learning system to address a wide range of healthcare issues; our ability to successfully amass the requisite data to achieve maximum network effects; appropriately allocating financial and human resources across a broad array of product and service offerings; raising additional capital as necessary to fund our operations; achieving significant commercial market acceptance for our sequencing and molecular analysis solutions; establish relationships with, key thought leaders or payers’ key decision makers in order to establish GPS Cancer as a standard of care for patients with cancer; our ability to grow the market for our Systems Infrastructure, and applications; successfully enhancing our Systems Infrastructure and applications to achieve market acceptance and keep pace with technological developments; customer concentration; competition; security breaches; bandwidth limitations; our ability to continue our relationship with NantOmics; our ability to obtain regulatory approvals; dependence upon senior management; the need to comply with and meet applicable laws and regulations; unexpected adverse events; clinical adoption and market acceptance of GPS Cancer; and anticipated cost savings. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our reports filed with the